It’s an unknown what drives the the market’s view on a valuation of the group. Vifor is less than 10% and is likely to become a smaller part as Behring is dominant and growing faster. I don’t think you can definitively say that Vifor has materially detracted the growth prospects of the group. And it remains accretive on current multiples.
recent Ferrinject approval , and now reimbursement , in China is potentially huge. An enormous population of iron deficient patients.
Ann: Results Announcement, page-88
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$307.78 |
Change
-0.140(0.05%) |
Mkt cap ! $148.1B | |||
| Open | High | Low | Value | Volume |
| $307.40 | $307.90 | $304.87 | $86.98M | 283.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 24 | 241 | $307.74 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $307.78 | 126 | 3 |
View Market Depth
| Last trade - 15.58pm 28/08/2024 (20 minute delay) ? |
| CSL (ASX) Chart |